Clinical studies recruiting near Cromwell

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Phase 3 · Ct Clinical Research Associates · Xenon Pharmaceuticals Inc. · NCT06775379 Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipol
Phase 2 · Connecticut Clinical Research - Cromwell /ID# 278116 · AbbVie · NCT07220460 Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Maj
Phase 3 · Neurocrine Clinical Site · Neurocrine Biosciences · NCT06966401 Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2 · Oruka Therapeutics Investigative Site · Oruka Therapeutics, Inc. · NCT07474792 Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Phase 3 · Clinical Research Site · Axsome Therapeutics, Inc. · NCT06413433 An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Phase 2 · Oruka Therapeutics Investigative Site · Oruka Therapeutics, Inc. · NCT07449702 Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Phase 3 · Clinical Research Site · Axsome Therapeutics, Inc. · NCT07398417 Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Phase 3 · CT Clinical Research · Pfizer · NCT04743141 Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Phase 3 · CT Clinical Research · Pfizer · NCT04649242 Hybrid Ablation of Atrial Fibrillation in Heart Failure
NA · St. George's Hospital, London · NCT05411614 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in
Phase 2 · Connecticut Clinical Research - Cromwell /ID# 271241 · AbbVie · NCT06846320 Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Phase 2 · Autobahn Site #122 · Autobahn Therapeutics, Inc. · NCT06633016 NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants W
Phase 3 · Neurocrine Clinical Site · Neurocrine Biosciences · NCT06963021 A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With
Phase 2 · Seaport Investigator Site · Seaport Therapeutics · NCT07065240

Look up another city

Look up another condition